Form 4 for BSX Boston Scientific
Accepted 2023-01-03 00:00:00 ET · period of report 2023-01-01 · accession 0001225208-23-000054 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| D | 2023-01-03 | 2023-01-01 | BSX | Thepaut Eric Francis Yves | EVP, Pres, Eur, Mid-East, Afr | M - OptEx | $0.00 | +7,092 | 64.6K | +12% | $0 |
| D | 2023-01-03 | 2023-01-01 | BSX | Thepaut Eric Francis Yves | EVP, Pres, Eur, Mid-East, Afr | F - Tax | $46.27 | -3,988 | 60.6K | -6% | -$184.5K |
| D | 2023-01-03 | 2023-01-01 | BSX | Thepaut Eric Francis Yves | EVP, Pres, Eur, Mid-East, Afr | M - OptEx | $0.00 | -7,092 | 0 | -100% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2023-01-01 | M | A | 7,092 | $0.00 | 64,625.99 | D | — | — | (F1) On February 18, 2020, the reporting person was awarded a target number of performance share units under the Company's 2020 Free Cash Flow Performance Share Program, the actual number of which to be earned by the reporting person would be based on the Company's 2020 adjusted free cash flow measured against its 2020 financial plan over the one-year performance period ending December 31, 2020 and subject to the completion of a three-year individual service period (inclusive of the performance period). On February 22, 2021, the number of the target performance share units as to which the performance criteria had been satisfied was determined. The performance share units so determined vested in whole upon completion of the individual service period that ended on December 31, 2022. |
| 2 | Common | Common Stock | 2023-01-01 | F | D | 3,988 | $46.27 | 60,637.99 | D | — | — | |
| 3 | Derivative | Performance Share Units | 2023-01-01 | M | D | 7,092 | $0.00 | 0 | D | — · 2022-12-31 to 2022-12-31 | 7,092 Common Stock | (F1) On February 18, 2020, the reporting person was awarded a target number of performance share units under the Company's 2020 Free Cash Flow Performance Share Program, the actual number of which to be earned by the reporting person would be based on the Company's 2020 adjusted free cash flow measured against its 2020 financial plan over the one-year performance period ending December 31, 2020 and subject to the completion of a three-year individual service period (inclusive of the performance period). On February 22, 2021, the number of the target performance share units as to which the performance criteria had been satisfied was determined. The performance share units so determined vested in whole upon completion of the individual service period that ended on December 31, 2022. (F2) Each performance share unit represents the Company's commitment to issue one share of Boston Scientific common stock. |